Hemanta Kumar Majumder

Kinetoplast DNA (kDNA) bearing unusual mitochondrion of trypanosomatid parasites offers a new paradigm in chemotherapy modality. Topoisomerase II of Leishmania donovani (LdTopII), a key enzyme associated with kDNA replication, is emerging as a potential drug target. However, mode of action of LdTopII targeted compounds in the parasites at sub-cellular level remains largely unknown. Previously, we reported that an isobenzofuranone derivative, namely 3,5-bis(4-chlorophenyl)-7-hydroxyisobenzofuran-1(3H)-one (JVPH3), targets LdTopII and induces apoptosis-like cell death in L. donovani. Here, we elucidate the phenotypic changes and the events occurring at sub-cellular level caused by JVPH3 in L. donovani. In addition, we have evaluated the cytotoxicity and ultrastructural alterations caused by JVPH3 in two brazilian trypanosomatid pathogens viz. L. amazonensis and Trypanosoma cruzi. Despite killing these parasites, JVPH3 caused significantly different phenotypes in L. donovani and L. amazonensis. More than 90% population of parasites showed altered morphology. Mitochondrion was a major target organelle subsequently causing kinetoplast network disorganization in Leishmania. Altered mitochondrial architecture was evident in 75–80% Leishmania population being investigated. Quantification of mitochondrial function using JC-1 fluorophore to measure a possible mitochondrial membrane depolarization further confirmed the mitochondrion as an essential target of the JVPH3 corroborating with the phenotype observed by electron microscopy. However, the impact of JVPH3 was lesser on T. cruzi than Leishmania. The molecule caused mitochondrial alteration in 40% population of the epimastigotes being investigated. To our knowledge, this is the first report to evaluate the proliferation pattern and ultrastructural alterations caused in Brazilian kinetoplastid pathogens by a synthetic LdTopII inhibitor previously established to have promising in vivo activity against Indian strain of L. donovani.

Written by authors active in the field of Leishmania and Trypanosoma research, this volume reviews the current research in kinetoplastid parasites with an emphasis on cellular and molecular biology. Includes epigenetic regulation, cellular defence, manipulation of host macrophages, B lymphocyte response, adhesion and invasion of host tissues, immune evasion, immunotherapy, hemeproteins, phospholipids biosynthesis and DNA topoisomerases.

The hydroxy‐9,10‐anthraquinones in anthracyclines form semiquinones and reactive oxygen species (ROS) that help in antitumor activity. ROS generation is cytotoxic to cells but cardiotoxic as well. Carminic acid (CA) with a sugar bound to a hydroxyanthraquinone resembles anthracyclines closely. Role of sugar in anthracyclines was realized from physicochemical parameters of CA that were found to be in between those of anthracyclines and hydroxy‐9,10‐anthraquinones. A Cu(II)complex of CA was prepared and its structure attempted from powder X‐ray diffraction. Studies with DNA revealed unlike CA, the complex did not show decrease in binding constant with increase in the pH of the medium. DNA relaxation assay showed the complex as a dual inhibitor of human DNA topoisomerase I and topoisomerase II stabilizing covalent topoisomerase‐DNA adducts in vitro. Inhibition of growth of ALL‐MOLT‐4 cells was higher for the complex supporting in vitro experiments. An enzyme assay revealed less superoxide formation for the complex suggesting that it might be less cardiotoxic. Decrease in superoxide for the complex does not affect anticancer activity, which was greater than CA.

DNA topoisomerases are important cellular enzymes found in almost all types of living cells (eukaryotic and prokaryotic). These enzymes are essential for various DNA metabolic processes e.g. replication, transcription, recombination, chromosomal decatenation etc. These enzymes are important molecular drug targets and inhibitors of these enzymes are widely used as effective anticancer and antibacterial drugs. However, topoisomerase inhibitors have some therapeutic limitations and they exert serious side effects during cancer chemotherapy. Thus, development of novel anticancer topoisomerase inhibitors is necessary for improving cancer chemotherapy. Nature serves as a repertoire of structurally and chemically diverse molecules and in the recent years many DNA topoisomerase inhibitors have been identified from natural sources. The present review discusses anticancer properties and therapeutic importance of eighteen recently identified natural topoisomerase inhibitors (from the year 2009 to 2015). Structural characteristics of these novel inhibitors provide backbones for designing and developing new anticancer drugs.

Visceral leishmaniasis is a fatal parasitic disease, and there is an emergent need for development of effective drugs against this neglected tropical disease. We report here the development of a novel spirooxindole derivative, N -benzyl-2,2′α-3,3′,5′,6′,7′,7α,α′-octahydro-2methoxycarbonyl-spiro[indole-3,3′-pyrrolizidine]-2-one (compound 4c), which inhibits Leishmania donovani topoisomerase IB (LdTopIB) and kills the wild type as well as drug-resistant parasite strains. This compound inhibits catalytic activity of LdTopIB in a competitive manner. Unlike camptothecin (CPT), the compound does not stabilize the DNA-topoisomerase IB cleavage complex; rather, it hinders drug-DNA-enzyme covalent complex formation. Fluorescence studies show that the stoichiometry of this compound binding to LdTopIB is 2:1 (mole/mole), with a dissociation constant of 6.65 μM. Molecular docking with LdTopIB using the stereoisomers of compound 4c produced two probable hits for the binding site, one in the small subunit and the other in the hinge region of the large subunit of LdTopIB. This spirooxindole is highly cytotoxic to promastigotes of L. donovani and also induces apoptosis-like cell death in the parasite. Treatment with compound 4c causes depolarization of mitochondrial membrane potential, formation of reactive oxygen species inside parasites, and ultimately fragmentation of nuclear DNA. Compound 4c also effectively clears amastigote forms of wild-type and drug-resistant parasites from infected mouse peritoneal macrophages but has less of an effect on host macrophages. Moreover, compound 4c showed strong antileishmanial efficacies in the BALB/c mouse model of leishmaniasis. This compound potentially can be used as a lead for developing excellent antileishmanial agents against emerging drug-resistant strains of the parasite.

Desgalactotigonin (DGT) and oleanolic acid 3-O-β-D-glucuronide (OAG) were isolated from Chenopodium album seeds, characterized using spectral analysis and evaluated for cytotoxic activity against various cancer cell lines. DGT and OAG induced apoptosis in a human breast cancer cell line (MCF-7) and were found to effectively inhibit human topoisomerases I and II in vitro. The study of the mode of enzyme inhibition revealed that both acted as catalytic inhibitors. IC₅₀ values for DGT and OAG on MCF-7 cells were found to be 8.27 μM and 11.33 μM respectively. Using FACS and western blot analysis, the compounds were observed to block the cell cycle at S phase. Activation of caspases 7 and 9 suggested that caspase pathways were involved in inducing apoptosis.

Although generation of reactive oxygen species (ROS) by anthracycline anticancer drugs is essential for anti-tumor activity, they make these drugs cardiotoxic. Metal–anthracyclines that generate relatively fewer ROS are however, effective antitumor agents. Purpurin (LH₃), a hydroxy-9,10-anthraquinone, closely resembles doxorubicin, an established anthracycline drug. This molecule was chosen to study the extent to which simpler analogues are effective. A Cu(II) complex of LH₃ [Cu^(II)–(LH₂)₂] was synthesized to mimic the metal–anthracycline complexes. The crystal structure of [Cu^(II)–(LH₂)₂] was determined by Rietveld refinement of PXRD data using an appropriate structural model developed on the basis of spectroscopic data. This is the first report on the crystal structure of any hydroxy-9,10-anthraquinone with a 3d-transition metal ion. The bond lengths and bond angles obtained by structural refinement corroborate those calculated by the DFT method. DNA binding of the complex was slightly better than purpurin. However, more importantly, unlike purpurin, binding constant values did not decrease with increasing pH of the medium. DNA relaxation assays show Cu^(II)–(LH₂)₂ as a novel potent dual inhibitor of human DNA topoisomerase I and topoisomerase II enzymes. Cu^(II)–(LH₂)₂ stabilizes covalent topoisomerase–DNA adducts both in vitro and within cancer cells. The cleavage assay keeps the complex well ahead of LH₃ with regard to efficacy. These results paralleled those of cell growth inhibition and showed that the complex was more effective in killing ALL MOLT-4 cells than LH₃, suggesting it targets topoisomerase enzymes within cells. The NADH dehydrogenase assay revealed further that the generation of superoxide was less in the case of the complex as compared to LH₃.